koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agentes antineoplásicos - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atópica - otras preparaciones dermatológicas - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
sunitinib tillomed 25 mg capsulas duras efg
laboratorios tillomed spain s.l. - sunitinib malato - cÁpsula dura - 25 mg - sunitinib malato 25 mg - sunitinib
sunitinib tillomed 12,5 mg capsulas duras efg
laboratorios tillomed spain s.l. - sunitinib malato - cÁpsula dura - 12,5 mg - sunitinib malato 12,5 mg - sunitinib
sunitinib tillomed 50 mg capsulas duras efg
laboratorios tillomed spain s.l. - sunitinib malato - cÁpsula dura - 50 mg - sunitinib malato 50 mg - sunitinib
sunitinib mylan 12,5 mg capsulas duras efg
mylan pharmaceuticals, s.l. - sunitinib - cÁpsula dura - 12,5 mg - sunitinib 12,5 mg - sunitinib
sunitinib mylan 25 mg capsulas duras efg
mylan pharmaceuticals, s.l. - sunitinib - cÁpsula dura - 25 mg - sunitinib 25 mg - sunitinib
sunitinib mylan 50 mg capsulas duras efg
mylan pharmaceuticals, s.l. - sunitinib - cÁpsula dura - 50 mg - sunitinib 50 mg - sunitinib
sunitinib teva 12,5 mg capsulas duras efg
teva b.v. - sunitinib - cÁpsula dura - 12,5 mg - sunitinib 12,5 mg - sunitinib
sunitinib teva 25 mg capsulas duras efg
teva b.v. - sunitinib - cÁpsula dura - 25 mg - sunitinib 25 mg - sunitinib